Cargando…
2773. Safety and Immunogenicity Study of Eastern Equine Encephalitis Vaccine
BACKGROUND: Eastern equine encephalitis virus (EEEV) is an alphavirus with a high mortality rate and serious neurological sequelae in infected persons making this virus an important human pathogen. METHODS: Following written informed consent, eligible subjects received two priming doses of EEEV vacc...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810637/ http://dx.doi.org/10.1093/ofid/ofz360.2450 |
_version_ | 1783462299657306112 |
---|---|
author | Maryam, Keshtkar-Jahromi Reisler, Ronald B Purcell, Bret K Rivard, Robert G Cardile, Anthony P Liggett, Dani Norris, Sarah Pitttman, Phillip R |
author_facet | Maryam, Keshtkar-Jahromi Reisler, Ronald B Purcell, Bret K Rivard, Robert G Cardile, Anthony P Liggett, Dani Norris, Sarah Pitttman, Phillip R |
author_sort | Maryam, Keshtkar-Jahromi |
collection | PubMed |
description | BACKGROUND: Eastern equine encephalitis virus (EEEV) is an alphavirus with a high mortality rate and serious neurological sequelae in infected persons making this virus an important human pathogen. METHODS: Following written informed consent, eligible subjects received two priming doses of EEEV vaccine, inactivated, TSI-GSD 104, 0.5 mL subcutaneously on days 0 and 28 days followed by a mandatory booster, 0.1 mL intradermal, at 6 months. Serum samples were collected pre-vaccination, days 21–35 following dose 2, as well as before and 21–35 days after dose 3. Sera with a Plaque Reduction Neutralization Test(80) titer (PRNT(80)) ≥ 1:40 were considered responders with adequate titers for the purpose of biocontainment suite entry. RESULTS: Sixty-seven (67) subjects were enrolled in this study to receive the primary vaccination series. All 67 subjects received at least 1 primary vaccination; 66 completed the 2 primary doses; 58 completed the 2 primary doses and the 6-month dose. Of these, 38 (56.7%) reported one or more adverse events. Fatigue was reported in 13 (19.4%), headache in 9 (13.4%), upper respiratory tract infection in 6 (9.0%), nausea in 5 (7.5%), pyrexia in 5 (7.5%), oropharyngeal pain in 4 (6.0%), myalgia in 4 (6.0%), injection site pain in 7 (10.4%), injection site hematoma in 4 (6.0%) and injection site erythema in 3 (4.5%) subjects. Adverse events were mostly mild or moderate and transient. PRNT(80) titers ≥ 1:40 was observed in 39/65 (60%) subjects who received both primary doses of EEEV vaccine compared with 48/57 (84%) subjects who completed the 2-dose primary series and the 6-month dose and also had blood drawn for titer. Females had a higher response rate (61.5%) at the pre 6-month boost titer than did males (34.3%) (p = 0.0231). Similarly, the pre 6-month boost geometric mean titer (GMT) for females was 35.5 vs. 21.9 for males (p = 0.0231). The post 6-month boost GMT for females was 146.7 and 181.5 for males (P = 0.13). CONCLUSION: Inactivated Eastern Equine Encephalitis Virus vaccine, TSI-GSD 104, Lot 2-1-89 appears to be safe and immunogenic. This Phase 2 vaccine study supports a priming dose schedule of Days 0 and 28 and 6-month. The 6 month dose is anamnestic improving the overall response rate and level of antibody for this primary dosing schedule. DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6810637 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68106372019-10-28 2773. Safety and Immunogenicity Study of Eastern Equine Encephalitis Vaccine Maryam, Keshtkar-Jahromi Reisler, Ronald B Purcell, Bret K Rivard, Robert G Cardile, Anthony P Liggett, Dani Norris, Sarah Pitttman, Phillip R Open Forum Infect Dis Abstracts BACKGROUND: Eastern equine encephalitis virus (EEEV) is an alphavirus with a high mortality rate and serious neurological sequelae in infected persons making this virus an important human pathogen. METHODS: Following written informed consent, eligible subjects received two priming doses of EEEV vaccine, inactivated, TSI-GSD 104, 0.5 mL subcutaneously on days 0 and 28 days followed by a mandatory booster, 0.1 mL intradermal, at 6 months. Serum samples were collected pre-vaccination, days 21–35 following dose 2, as well as before and 21–35 days after dose 3. Sera with a Plaque Reduction Neutralization Test(80) titer (PRNT(80)) ≥ 1:40 were considered responders with adequate titers for the purpose of biocontainment suite entry. RESULTS: Sixty-seven (67) subjects were enrolled in this study to receive the primary vaccination series. All 67 subjects received at least 1 primary vaccination; 66 completed the 2 primary doses; 58 completed the 2 primary doses and the 6-month dose. Of these, 38 (56.7%) reported one or more adverse events. Fatigue was reported in 13 (19.4%), headache in 9 (13.4%), upper respiratory tract infection in 6 (9.0%), nausea in 5 (7.5%), pyrexia in 5 (7.5%), oropharyngeal pain in 4 (6.0%), myalgia in 4 (6.0%), injection site pain in 7 (10.4%), injection site hematoma in 4 (6.0%) and injection site erythema in 3 (4.5%) subjects. Adverse events were mostly mild or moderate and transient. PRNT(80) titers ≥ 1:40 was observed in 39/65 (60%) subjects who received both primary doses of EEEV vaccine compared with 48/57 (84%) subjects who completed the 2-dose primary series and the 6-month dose and also had blood drawn for titer. Females had a higher response rate (61.5%) at the pre 6-month boost titer than did males (34.3%) (p = 0.0231). Similarly, the pre 6-month boost geometric mean titer (GMT) for females was 35.5 vs. 21.9 for males (p = 0.0231). The post 6-month boost GMT for females was 146.7 and 181.5 for males (P = 0.13). CONCLUSION: Inactivated Eastern Equine Encephalitis Virus vaccine, TSI-GSD 104, Lot 2-1-89 appears to be safe and immunogenic. This Phase 2 vaccine study supports a priming dose schedule of Days 0 and 28 and 6-month. The 6 month dose is anamnestic improving the overall response rate and level of antibody for this primary dosing schedule. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810637/ http://dx.doi.org/10.1093/ofid/ofz360.2450 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Maryam, Keshtkar-Jahromi Reisler, Ronald B Purcell, Bret K Rivard, Robert G Cardile, Anthony P Liggett, Dani Norris, Sarah Pitttman, Phillip R 2773. Safety and Immunogenicity Study of Eastern Equine Encephalitis Vaccine |
title | 2773. Safety and Immunogenicity Study of Eastern Equine Encephalitis Vaccine |
title_full | 2773. Safety and Immunogenicity Study of Eastern Equine Encephalitis Vaccine |
title_fullStr | 2773. Safety and Immunogenicity Study of Eastern Equine Encephalitis Vaccine |
title_full_unstemmed | 2773. Safety and Immunogenicity Study of Eastern Equine Encephalitis Vaccine |
title_short | 2773. Safety and Immunogenicity Study of Eastern Equine Encephalitis Vaccine |
title_sort | 2773. safety and immunogenicity study of eastern equine encephalitis vaccine |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810637/ http://dx.doi.org/10.1093/ofid/ofz360.2450 |
work_keys_str_mv | AT maryamkeshtkarjahromi 2773safetyandimmunogenicitystudyofeasternequineencephalitisvaccine AT reislerronaldb 2773safetyandimmunogenicitystudyofeasternequineencephalitisvaccine AT purcellbretk 2773safetyandimmunogenicitystudyofeasternequineencephalitisvaccine AT rivardrobertg 2773safetyandimmunogenicitystudyofeasternequineencephalitisvaccine AT cardileanthonyp 2773safetyandimmunogenicitystudyofeasternequineencephalitisvaccine AT liggettdani 2773safetyandimmunogenicitystudyofeasternequineencephalitisvaccine AT norrissarah 2773safetyandimmunogenicitystudyofeasternequineencephalitisvaccine AT pitttmanphillipr 2773safetyandimmunogenicitystudyofeasternequineencephalitisvaccine |